Eloxx Pharmaceuticals Inc

NASDAQ:ELOX   3:59:03 PM EDT
0.73
+0.01 (+0.87%)
Products, Regulatory

Eloxx Pharmaceuticals Reports Positive Topline Results From Phase 2 Clinical Trial Of Elx-02 In Class 1 Cystic Fibrosis Patients

Published: 11/17/2021 12:19 GMT
Eloxx Pharmaceuticals Inc (ELOX) - Eloxx Pharmaceuticals Reports Positive Topline Results From Monotherapy Arms of Phase 2 Clinical Trial of Elx-02 in Class 1 Cystic Fibrosis Patients.
Eloxx Pharmaceuticals Inc - Elx-02 Monotherapy Results Support Advancement of Elx-02 Into Phase 3 Clinical Development.
Eloxx Pharmaceuticals Inc - Topline Data From Phase 2 Elx-02 Expected by End of First Half of 2022.
Eloxx - Elx-02 Was Well Tolerated and Achieved a Statistically Significant 5.4mmol/l Reduction in Sweat Chloride in Patients at The1.5mg/kg/day Dose.
Eloxx Pharmaceuticals Inc - Expect to Submit an Investigational New Drug Application in Second Half of 2022.